What is the recommended dosage of Olazapibe (generic name) for a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Olanzapine Dosage Recommendations

The recommended starting dose of olanzapine for adults is 5-10 mg orally once daily, with a target dose of 10 mg/day for schizophrenia and bipolar disorder, and doses can be adjusted within the range of 5-20 mg/day based on clinical response. 1

Standard Adult Dosing

Schizophrenia

  • Initial dose: 5-10 mg once daily 1
  • Target dose: 10 mg/day 1
  • Maintenance range: 5-20 mg/day 1
  • Doses above 10 mg/day should only be considered after clinical assessment 1
  • Safety and efficacy of doses above 20 mg/day have not been established 1

Bipolar I Disorder (Acute Mania)

  • Initial dose: 10-15 mg once daily as monotherapy 1
  • When combined with lithium or valproate, start at 10 mg once daily 1
  • Dosage range: 5-20 mg/day 1

Acute Agitation (Intramuscular)

  • Recommended dose: 10 mg intramuscular 1
  • Lower doses of 5 mg or 7.5 mg may be considered when clinical factors warrant 1
  • Subsequent doses up to 10 mg may be given if agitation persists 1
  • Maximum: 30 mg total daily dose, with injections spaced at least 2-4 hours apart 1

Special Population Adjustments

Elderly Patients

  • Consider lower starting doses (5 mg/injection for intramuscular, 5 mg/day for oral) 1
  • The American Geriatrics Society recommends using lower starting doses for elderly patients 2, 3
  • Dose reduction to 5 mg may be considered in elderly or oversedated patients 4

Hepatic Impairment

  • Lower starting doses should be considered 2
  • The American Association for the Study of Liver Diseases recommends reduced initial dosing 3

Debilitated or Pharmacodynamically Sensitive Patients

  • Consider 2.5 mg/injection for intramuscular administration 1
  • Consider 5 mg/day for oral administration 1

Adolescent Dosing (Ages 13-17)

Schizophrenia

  • Titration schedule: 3
    • Days 1-2: 2 mg/day
    • Days 3-4: 5 mg/day
    • Day 5 and beyond: 10 mg/day
  • Target dose: 10 mg/day 1
  • Range: 2.5-20 mg/day 1

Bipolar I Disorder (Acute Mania)

  • Initial dose: 2.5-5 mg once daily 1
  • Target dose: 10 mg/day 1
  • Doses above 20 mg/day have not been evaluated 1

Pediatric Dosing (Ages 6-17)

Autism Spectrum Disorder

  • Dose range: 5-15 mg/day 3
  • Fixed doses of 5,10, or 15 mg/day have been studied with response rates of 56% at 5 mg versus 35% on placebo 3

Combination Therapy

With Fluoxetine (Bipolar Depression)

  • Start with 5 mg olanzapine + 20 mg fluoxetine once daily in the evening 1
  • Dosage range: olanzapine 5-12.5 mg with fluoxetine 20-50 mg 1
  • Efficacy demonstrated with olanzapine 6-12 mg and fluoxetine 25-50 mg 1
  • Safety above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated 1

Pharmacokinetic Considerations

  • Mean elimination half-life: approximately 75 hours (range 21-54 hours) 2, 5
  • Plasma clearance is approximately 26 L/h (range 12-47 L/h) 5
  • Smokers and men have higher clearance than women and nonsmokers 5
  • Fluvoxamine (CYP1A2 inhibitor) increases olanzapine concentrations; carbamazepine and smoking decrease concentrations 5

Critical Safety Considerations

  • Maximal intramuscular dosing (3 doses of 10 mg at 2-4 hour intervals) may cause significant orthostatic hypotension 1
  • Assess for orthostatic hypotension before administering subsequent intramuscular doses 1
  • Do not combine intramuscular olanzapine with diazepam (causes precipitation) or lorazepam (delays reconstitution) 1
  • Most common adverse effects include weight gain, somnolence, dizziness, dry mouth, and constipation 6, 7

References

Guideline

Aripiprazole Dosage Considerations for Adults with Schizophrenia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Aripiprazole Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Clinical pharmacokinetics, 1999

Research

Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.